Guardian Pharmacy Services enters the post-earnings period having delivered a clean beat — but with short sellers who spent six weeks building positions now facing a squeeze they didn't quite get.
Q1 results landed after the close on May 6. Adjusted EPS came in at $0.29, beating the $0.23 consensus estimate. Revenue of $336.6M cleared the $329.5M bar. Management affirmed full-year 2026 sales guidance of $1.40B–$1.42B, bracketing the $1.41B Street estimate almost exactly. The guidance hold is notable given the expansion narrative: bears have argued that Guardian's acquisition-heavy growth model delays meaningful earnings power, typically requiring up to four years for new facilities to reach full potential. A reaffirmed top-line range doesn't fully answer that challenge, but it removes one obvious bear catalyst.
The short interest story is what makes this week's setup genuinely unusual. SI % of free float climbed from roughly 10% at the end of March to a peak above 16% in mid-April before dropping sharply around April 23 — a single-session reduction of nearly 450,000 shares. It then rebuilt, arriving at the earnings print at 14.1% of the float. That is a crowded, not cautious, position. The 30-day increase in short shares was 32%, a meaningful acceleration. Availability has remained relatively loose throughout — short sellers have had plenty of room to build — and borrow cost has been inexpensive at 0.57% annualised, confirming the thesis-driven rather than technically-forced nature of the position. Lending market conditions have tightened since March (the 52-week high in utilization of 35.7% came earlier in the period), but the current setup suggests ample capacity for shorts to cover or add.
Options, by contrast, have been pulling back from peak defensiveness. The put/call ratio ran above 4 for much of late April and hit 5.8 at its most extreme on April 24. By May 5 it had dropped back to 2.95, near its 20-day average of 3.31. A PCR above 3 is still well-elevated in absolute terms, and the 52-week range runs from 0 to 10.7 — but the directional move is notable. Options protection demand was highest in the days before the print and eased into it. That easing, combined with the earnings beat, may now force some reconsideration among the more defensive options positioning.
The analyst community has been constructive and unusually active for a mid-cap name. B of A Securities initiated with a Buy and a $42 target on April 27 — the most recent entry by a major firm and one that changes the composition of coverage rather than merely adjusting a target. Jefferies started at Buy with a $44 target in late March. Truist, which has been covering the name since at least mid-2025, raised its target to $43 from $38 in mid-April. Oppenheimer moved its target to $38 earlier in the year. The result is five buy-equivalent ratings, targets clustering in the low-to-mid $40s against a pre-earnings close of $37.24, and a consensus that has been upgrading its view rather than trimming. EPS surprise ranks in the 80th percentile across the universe, and 90-day EPS momentum is near the 78th percentile — the quality-of-earnings picture supports the Street's constructive lean.
One angle the Street's enthusiasm doesn't fully resolve is the insider activity in March. On March 20, Guardian's founder and CEO Fred Burke sold 671,432 shares at $29.68, realising roughly $19.9M. The CFO, David Morris, sold 187,855 shares the same day. Bindley Capital Partners — the largest holder with 26.3% of shares — trimmed 3.57 million shares on the same date, reducing its stake but remaining the dominant investor. These were secondary sales executed in concert, the kind of transaction that typically follows a registration event rather than signalling any one individual's read on near-term fundamentals. The fact that the stock is now 25% above those March sale prices suggests the sellers left material performance on the table. BlackRock and Vanguard, meanwhile, both added to positions in the March-April reporting period — a passive/institutional counter-trend worth noting.
The next confirmed event is May 12. With Q1 already cleared and full-year guidance held, the conversation now shifts to whether the short interest rebuilt ahead of earnings begins to unwind — or whether bears use the guidance hold as evidence that margin expansion remains a later-cycle story. The ORTEX short score of 57.8 sits in the middle of its recent range, neither extreme. What to watch: whether SI % of float, which came into earnings at 14% after spending three weeks above 15%, now tracks lower in the absence of fresh negative catalysts.
See the live data behind this article on ORTEX.
Open GRDN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
